It's the big numbers that tend to make headlines during earnings season: Overall sales, top-selling meds, and, of course, earnings per share. Some closely watched new drugs have a moment in the sun, too. But other launches? Barely a glimpse--if any at all. Here's a roundup of the launch stats that caught our eyes.
Pfizer's Viagra sales may be suffering from generic rivals in Europe. But the brand is still going gangbusters in China, helping to soften the blow.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
No one can pin down Pfizer CEO Ian Read when it comes to whether the company will split up--not publicly, anyway. That word won't come till late next year at least. But repeated questioning from analysts during the company's first-quarter earnings call did yield some facts in the matter.
Hospira has worked itself out from under the warning letters for its pharma manufacturing plants in Rocky Mount and Clayton, NC. That means that Pfizer, which is buying Hospira in a $17 billion deal, will not have that hanging over its head, although the company still has plenty of other regulatory issues with which Pfizer will have to contend.
Pfizer's recent vaccines moves are beginning to pay off for the New York pharma. On Tuesday, riding expectation-breaking numbers for its lead jab, the business reported a 44% increase in first-quarter revenue.
Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials.
Pfizer may have had to whittle down its full-year revenue and profit forecasts on Tuesday on account of a stronger dollar. But as far as Q1 goes, the drugmaker churned out hauls in both categories that topped Wall Street's expectations.
Injectable drug specialist Hospira, which is being bought by Pfizer, blew past analysts' projections for its Q1 earnings today, but its manufacturing issues continue to be a drag. Just last week, the FDA said Hospira had issued a recall of an anesthetic because iron particles had been found in some vials.
Orphan meds have been like catnip for drugmakers for several years, driving many an M&A deal. Now, Swedish Orphan Biovitrum might be next in line, at a price of more than $3.5 billion.